Customized ablations following IOL implantation = spectacle independence
Following enhancement with IntraLase bioptics, nearly all patients with high preoperative astigmatism can achieve spectacle independence.
Following enhancement with IntraLase bioptics, nearly all patients with high preoperative astigmatism can achieve spectacle independence, according to Michael Knorz from the University Hospital, Mannheim, Germany.
Dr Knorz bilaterally implanted multifocal IOLs (Tecnis aspheric MF or ReZoom; AMO) into 14 patients with hyperopia and astigmatism of more than 2 D. A femtosecond-laser flap (IntraLase FS-60) of 100 microns and 9 mm was created immediately prior to lens surgery without lifting it. In eyes implanted with the Tecnis lens, a wavefront-guided ablation was performed, meanwhile in eyes implanted with the ReZoom lens, a standard ablation was performed with the Visx Star S4 (AMO) to fine tune the refraction.
Following implantation of the IOLs, average sphere was +0.85 and average cylinder was +1.04. After laser enhancement, sphere was +0.12 and cylinder +0.23. Higher order aberrations decreased significantly from 0.6 after IOL implantation to 0.32 after laser correction. No patient required spectacles postoperatively.
Dr Knorz believes that customized ablations following IOL implantation allows most patients to achieve spectacle independence and decreases the incidence of higher order aberrations.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.
